<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03618953</url>
  </required_header>
  <id_info>
    <org_study_id>Ad-MG1-E6E7-002</org_study_id>
    <nct_id>NCT03618953</nct_id>
  </id_info>
  <brief_title>This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated Cancers</brief_title>
  <acronym>Kingfisher</acronym>
  <official_title>Phase 1/1b, Multicenter, Open-label Trial of Oncolytic MG1 Virus (MG1-E6E7) With Adenovirus Vaccine (Ad-E6E7) Both Expressing Mutant Human Papilloma Virus (HPV) E6 and E7 and Atezolizumab in Pts With HPV Assoc. Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turnstone Biologics, Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turnstone Biologics, Corp.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/1b open-label dose escalation trial of Ad/MG1-E6E7 and sequential treatment&#xD;
      with atezolizumab in patients with HPV associated cancers. This study will consist of two&#xD;
      arms. Both arms will dose escalate (MG1-E6E7) using a 3 + 3 design in Phase 1 to establish&#xD;
      initial safety and the maximum tolerated dose (MTD) / maximum feasible dose (MFD).&#xD;
&#xD;
        -  Arm 1 - intravenous (IV) administration of MG1-E6E7 following intramuscular (IM) AD-E6E7&#xD;
           priming and subsequent treatment with IV atezolizumab.&#xD;
&#xD;
        -  Arm 2 - intratumoral (IT) and IV injection of MG1-E6E7 following (IM) Ad-E6E7 priming&#xD;
           and subsequent treatment with IV atezolizumab.&#xD;
&#xD;
      In the Phase 1b expansion for each arm, additional patients will be enrolled at the MTD as&#xD;
      determined in Phase 1 in order to more thoroughly explore immune response,&#xD;
      pharmacokinetics/dynamics, and safety for the patient populations with Cervical cancer, HPV&#xD;
      positive (HPV+) Oropharyngeal cancer (Phase 1B, Arm 1, Cohorts A and B respectively) and HPV+&#xD;
      tumors with injectable lesions (Phase 1B, Arm 2, Cohort 3).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 21, 2018</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Actual">April 15, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of Ad/MG1-E6E7 administration in HPV associated cancers</measure>
    <time_frame>8 months</time_frame>
    <description>Safety will be determined by assessing the severity and frequency of treatment emergent Adverse Events and clinical laboratory toxicity using NCI CTCAE v 4.03.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the maximum tolerated dose (MTD)/ maximum feasible dose (MFD) of Ad/MG1-E6E7 in HPV associated cancers</measure>
    <time_frame>4 to 6 weeks after first treatment with Ad/MG1-E6E7</time_frame>
    <description>MTD/MFD of Ad/MG1-E6E7 administered by IV infusion alone and IV infusion followed by direct injection of tumor (IT injection) in HPV associated cancers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of Ad/MG1-E6E7 in blood</measure>
    <time_frame>4 to 6 weeks after first treatment with Ad/MG1-E6E7</time_frame>
    <description>Change over time in the number of MG1-E6E7 genomes (qPCR) and MG1-E6E7 infectious units (PFU) in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess for the biodistribution and shedding of Ad/MG1-E6E7</measure>
    <time_frame>6 weeks after first treatment with Ad/MG1-E6E7</time_frame>
    <description>Determine if there is any shedding of Ad/MG1-E6E7 into the environment by detecting the presence of viral plaque forming units (PFUs) in urine samples, cheek swabs, and rectal swabs after Ad/MG1-E6E7 treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure the differences in pre- and post treatment levels of T cell subsets and T cell activation status</measure>
    <time_frame>Before and after each dose of Ad/MG1-E6E7 and then every 3 weeks until treatment discontinuation</time_frame>
    <description>Analyze the change over time in the the frequencies, absolute numbers and subsets of T cells (including regulatory T cells)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity</measure>
    <time_frame>Every 6 weeks for the first course of treatment and then every 9 weeks until date of documented progression by irRECIST, up to 2 years</time_frame>
    <description>Evaluate tumor response by CT scan using RECIST v1.1 and irRECIST criteria in the overall patient population and the HPV16/18 positive patient population</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>HPV-Associated Cancers</condition>
  <arm_group>
    <arm_group_label>Arm 1 (Intravenous dosing)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose of Ad-E6E7 administered IM on study Day 1. Followed by one of 3 dose levels (escalation) of MG1-E6E7 administered as 4 infusion (IV) doses over 2 weeks starting at study day 15.&#xD;
Fixed dose of atezolizumab administered IV every 3weeks starting at study day 43.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 (Intravenous and Intra-tumoral injection dosing)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose of Ad-E6E7 administered IM on study Day 1. Followed by one of 2 dose levels (escalation) of MG1-E6E7 administered as 1 IV dose, starting at study day 15, followed by 2 intratumoral (IT) doses administered on study days 18 &amp; 29.&#xD;
Fixed dose of atezolizumab administered IV every 3weeks starting at study day 43.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad-E6E7</intervention_name>
    <description>Adenovirus vaccine expressing mutant HPV E6 and E7</description>
    <arm_group_label>Arm 1 (Intravenous dosing)</arm_group_label>
    <arm_group_label>Arm 2 (Intravenous and Intra-tumoral injection dosing)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MG1-E6E7</intervention_name>
    <description>MG1 Maraba oncolytic virus expressing mutant HPV E6 and E7</description>
    <arm_group_label>Arm 1 (Intravenous dosing)</arm_group_label>
    <arm_group_label>Arm 2 (Intravenous and Intra-tumoral injection dosing)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>monoclonal antibody; checkpoint inhibitor</description>
    <arm_group_label>Arm 1 (Intravenous dosing)</arm_group_label>
    <arm_group_label>Arm 2 (Intravenous and Intra-tumoral injection dosing)</arm_group_label>
    <other_name>Tecentriq</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed recurrent or metastatic HPV associated tumor&#xD;
             (cervical, oropharyngeal, vulvar, vaginal, anal, or penile) with documented disease&#xD;
             progression.&#xD;
&#xD;
          -  Arm 1, Phase 1 dose escalation: Cervical, HPV+ oropharyngeal, vulvar, vaginal, anal,&#xD;
             or penile&#xD;
&#xD;
          -  Arm 1, Cohort A: Cervical cancer&#xD;
&#xD;
          -  Arm 1, Cohort B: HPV+ Oropharyngeal cancer&#xD;
&#xD;
          -  Arm 2 Phase 1 dose escalation and Cohort C: Cervical, oropharyngeal, vulvar, vaginal,&#xD;
             anal, or penile&#xD;
&#xD;
          -  Failed, refused or intolerant to systemic therapy&#xD;
&#xD;
          -  Measurable disease based on RECIST 1.1&#xD;
&#xD;
          -  At least one tumor mass amenable to core needle biopsy&#xD;
&#xD;
          -  Arm 2 only: At least one tumor judged as being safely injectable&#xD;
&#xD;
          -  ECOG performance status 0 or 1&#xD;
&#xD;
          -  Demonstrate adequate organ function&#xD;
&#xD;
          -  Additional Inclusion criteria exist&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Prior systemic therapy within 4 weeks.&#xD;
&#xD;
          -  Patients receiving prior XRT must have recovered from any acute toxicity.&#xD;
&#xD;
          -  Currently receiving/received experimental therapy within 4 weeks.&#xD;
&#xD;
          -  Prior treatment with any HPV vaccine therapy for cancer.&#xD;
&#xD;
          -  Requires use of anti-platelet or anti-coagulant therapy that cannot be safely&#xD;
             suspended for per protocol biopsies or intra-tumoral injections.&#xD;
&#xD;
          -  Known active CNS metastases and/or carcinomatous meningitis.&#xD;
&#xD;
          -  Clinically significant tumor invasion/ rapidly accumulating ascites, pericardial or&#xD;
             pleural effusions.&#xD;
&#xD;
          -  Active infection requiring systemic therapy.&#xD;
&#xD;
          -  Active autoimmune disease that has required systemic therapy in the past 2 years.&#xD;
&#xD;
          -  Conditions likely to have resulted in splenic dysfunction.&#xD;
&#xD;
          -  Known HIV/AIDS, active HBV or HCV infection.&#xD;
&#xD;
          -  Received prior treatment with vesicular stomatitis (VSV) viral vector.&#xD;
&#xD;
          -  Received immunosuppressive medication within 4 weeks. (&gt;10mg/day prednisone)&#xD;
&#xD;
          -  â‰¥ Grade 2 dyspnea and/or require supplemental oxygen&#xD;
&#xD;
          -  Known intolerance to anti-PD-1 or anti-PD-L1 antibody therapy&#xD;
&#xD;
          -  Additional Exclusion criteria exist&#xD;
&#xD;
        Exclusion Criteria Household Contacts:&#xD;
&#xD;
          -  Patients with household contacts meeting any of the following criteria are ineligible&#xD;
             for study entry unless alternate living arrangements can be made, while under contact&#xD;
             precautions.&#xD;
&#xD;
          -  Women who are pregnant or nursing an infant&#xD;
&#xD;
          -  Children &lt; 1 year old&#xD;
&#xD;
          -  Individuals who are severely immunocompromised&#xD;
&#xD;
          -  Contact precautions are from initial treatment with MG1-E6E7 to 7 days after the last&#xD;
             dose of MG1-E6E7&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Bernstein, MD</last_name>
    <role>Study Director</role>
    <affiliation>Turnstone Biologics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Billings Clinic</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Toledo-The Eleanor N. Dana Cancer Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas-MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 22, 2018</study_first_submitted>
  <study_first_submitted_qc>August 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2018</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

